Revealing the adipose vascular niche

Revealing the adipose vascular niche

  • Ibrahim AlZaim
  • Mohamed N. Hassan
  • Joanna Kalucka
Resource

Announcements

  • Scale

    Nature Metabolism participates in this collection together with other journals across the Nature Portfolio.This collection welcomes the submission of clinical and preclinical work that explores all aspects of obesity, including causes, pathophysiological mechanisms, incidence, and impact, as well as approaches to prevent or treat obesity, such as GLP-1 agonists alone or in combination therapies.

    Open for submissions
  • Crossing arrows

    The Career Pathways series features the stories of Nature Metabolism authors and their self-professed journeys to publication as young investigators. This Collection brings together the Career Pathway pieces and the original research published in Nature Metabolism by the authors.

  • Striated skeletal muscle

    Nature Metabolism participates in this collection together with other journals across the Nature Portfolio. This collection welcomes submissions on myogenesis, muscle metabolism, muscle regeneration and response to exercise, as well as muscle wasting in the context of ageing and cachexia.

    Open for submissions
  • Nature Conference announcement

    This Collection of articles, published in Nature Metabolism, aims to highlight best practices in experimental design, analysis and reporting to support the metabolic research community and increase reproducibility of research in the life sciences.

Advertisement

  • Although long-chain acyl-CoA esters are essential to virtually every aspect of lipid metabolism, their regulatory and signalling roles remain underappreciated. These molecules deserve far greater attention than they receive, because their spatially restricted formation and tightly regulated abundance endow them with potent and highly specific metabolic cues.

    • Nils J. Færgeman
    Comment
  • Incretin-based therapies have revolutionized the treatment of obesity and related metabolic disorders. On World Obesity Day (4 March), we discuss incretin-based therapies as go-to treatments for obesity and its comorbidities, highlighting triumphs and cautionary tales.

    Editorial
  • Adjusting energy expenditure for body composition and visualizing the results are key to understanding the role of energy expenditure in human physiology and disease. Here, we outline specific analysis of covariance modelling and the design of partial residual plots optimized for analysing human energy expenditure data.

    • Rodrigo Fernández-Verdejo
    • Kaja Falkenhain
    • Eric Ravussin
    Comment
  • The glucagon-like peptide 1 receptor agonist (GLP-1RA) class of medicines has emerged as transformative for the treatment of diabetes, obesity and other diseases. On the twentieth anniversary of the approval of exenatide (Byetta), three former employees of Amylin Pharmaceuticals acknowledge the contributions of some of the individuals and the innovation responsible for delivering the first approved GLP-1RA — the forerunner to the modern blockbuster drugs.

    • James L. Trevaskis
    • David G. Parkes
    • Andrew A. Young
    Comment
  • Social media has become a go-to source for nutritional advice, and a space in which influencers compete with, and often drown out, evidence-based guidance. The scientific community should counter this viral spread of misinformation by making trustworthy information more accessible.

    Editorial